It was found that miR-296-3p downregulated SOX4 by targeting the Wnt/β-catenin signaling pathway to produce anti-tumor effects in TNBC [76], while miR-638 downregulation is associated with poor prognosis in BC patients, and its suppression of HOXA9 and the Wnt/β-catenin signaling pathway can inhibit BC progression [77]. The gene discussed is SOX4; the disease is breast cancer.